Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta (axicabtagene ciloleucel) and Mavrilimumab for R/R Large B-Cell Lymphoma

 Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta (axicabtagene ciloleucel) and Mavrilimumab for R/R Large B-Cell Lymphoma

Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta (axicabtagene ciloleucel) and Mavrilimumab for R/R Large B-Cell Lymphoma

Shots:

  • Kite and Kiniksa enter into a clinical collaboration to conduct a P-II study assessing Yescarta + mavrilimumab in patients with r/r LBCL. Kite will sponsor and conduct the study
  • The P-II study will determine the effect of GM-CSFRα inhibition with mavrilimumab on the clinical safety of Yescarta. The collaboration supports Kiniksa’s objective to develop therapies targeting unmet medical needs
  • Mavrilimumab is an investigational mAb, designed to antagonize GM-CSF signaling by binding to the alpha subunit of the GM-CSF receptor while Yescarta is the first CAR T cell therapy to be approved by the US FDA to treat patients with r/r LBCL prior treated with 2L+ systemic therapy

Click here to­ read full press release/ article | Ref: Kiniksa | Image: News India times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post